ATE300291T1 - Behandlung von krebs mit tetraethylthiuramdisulfid - Google Patents

Behandlung von krebs mit tetraethylthiuramdisulfid

Info

Publication number
ATE300291T1
ATE300291T1 AT99963914T AT99963914T ATE300291T1 AT E300291 T1 ATE300291 T1 AT E300291T1 AT 99963914 T AT99963914 T AT 99963914T AT 99963914 T AT99963914 T AT 99963914T AT E300291 T1 ATE300291 T1 AT E300291T1
Authority
AT
Austria
Prior art keywords
disulfide
tetraethylthiurame
treating cancer
tetraethylthiuram disulfide
growth
Prior art date
Application number
AT99963914T
Other languages
English (en)
Inventor
Thomas Preston Kennedy
Original Assignee
Charlotte Mecklenburg Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charlotte Mecklenburg Hospital filed Critical Charlotte Mecklenburg Hospital
Application granted granted Critical
Publication of ATE300291T1 publication Critical patent/ATE300291T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y116/00—Oxidoreductases oxidizing metal ions (1.16)
    • C12Y116/03—Oxidoreductases oxidizing metal ions (1.16) with oxygen as acceptor (1.16.3)
    • C12Y116/03001—Ferroxidase (1.16.3.1), i.e. ceruloplasmin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99963914T 1999-09-08 1999-11-15 Behandlung von krebs mit tetraethylthiuramdisulfid ATE300291T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/392,122 US6589987B2 (en) 1998-09-08 1999-09-08 Method of treating cancer using tetraethyl thiuram disulfide
PCT/US1999/027193 WO2001017522A1 (en) 1999-09-08 1999-11-15 Method of treating cancer using tetraethyl thiuram disulfide

Publications (1)

Publication Number Publication Date
ATE300291T1 true ATE300291T1 (de) 2005-08-15

Family

ID=23549328

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99963914T ATE300291T1 (de) 1999-09-08 1999-11-15 Behandlung von krebs mit tetraethylthiuramdisulfid

Country Status (9)

Country Link
US (1) US6589987B2 (de)
EP (1) EP1214063B1 (de)
JP (1) JP2003514769A (de)
AT (1) ATE300291T1 (de)
AU (1) AU782029B2 (de)
CA (1) CA2384059C (de)
DE (1) DE69926407T2 (de)
ES (1) ES2244237T3 (de)
WO (1) WO2001017522A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816403B2 (en) * 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
US6548540B2 (en) * 1998-09-08 2003-04-15 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
WO2002056823A2 (en) * 2001-01-18 2002-07-25 Arnold Hoffman Redox therapy for tumors
US20030073609A1 (en) * 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
WO2006104396A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Pre-complexed copper antagonist compositions
WO2008068746A2 (en) * 2006-12-04 2008-06-12 Yeda Research And Development Co. Ltd. Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders
US20120030779A1 (en) 2007-01-18 2012-02-02 University Of Utah Research Foundtion Compositions and methods for detecting, treating, or preventing reductive stress
KR20110013366A (ko) * 2008-03-17 2011-02-09 유타대학연구재단 디티오카르바메이트 금속 킬레이트 및 그 제조 및 사용 방법
GB201020860D0 (en) * 2010-12-09 2011-01-26 Univ Wolverhampton Disulfiram formulation and uses thereof
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
WO2017049529A1 (en) 2015-09-24 2017-03-30 Innolife Co., Ltd. A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
EP3311843A1 (de) 2016-10-13 2018-04-25 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Zusammensetzungen enthaltend dithiocarbamat und cyclodextrin
EP3532039A4 (de) 2016-10-26 2020-07-15 Cantex Pharmaceuticals, Inc. Zeitlich versetztes orales dosierungsschema mit disulfiram und metallsalz und orale einheitsdosierungsformen mit zeitlich versetzter freisetzung
DK3459526T3 (da) 2017-09-26 2021-05-25 Palacky Univ In Olomouc Biotilgængelige dithiocarbamat-metalkompleks-nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf
KR20190056758A (ko) 2017-11-17 2019-05-27 주식회사 지뉴브 종양줄기세포 특성의 암을 치료하기 위한 항암 병용 요법
EP3693740A1 (de) * 2019-02-07 2020-08-12 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Verbesserte dithiocarmabatbasierende verbindungen, therapien und diagnostik
CN111135175B (zh) * 2020-01-17 2022-09-16 中国医学科学院放射医学研究所 Dsf-2在制备抗肿瘤和抗辐射药物中的应用
WO2021257880A1 (en) * 2020-06-18 2021-12-23 Spring Discovery, Inc. Use of aldh modulators or gasdermin d inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system
US11351128B1 (en) * 2021-05-13 2022-06-07 Lance L. Gooberman Pharmaceutical compositions and methods of administration
CN114010624B (zh) * 2021-12-13 2023-03-28 上海纳米技术及应用国家工程研究中心有限公司 双硫仑和甲氨蝶呤在制备抗肝癌药物中的应用
WO2024046332A1 (zh) * 2022-08-29 2024-03-07 石贵中 医药组合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148885A (en) 1973-09-25 1979-04-10 Institut Merieux Immunostimulant medicine
US4581224A (en) 1980-08-08 1986-04-08 Regents Of The University Of Minnesota Inhibition of undesired effect of platinum compounds
US4594238A (en) 1980-08-08 1986-06-10 Regents Of University Of Minnesota Inhibition of undesired effect of platinum compounds
US4426372A (en) 1980-08-08 1984-01-17 Regents Of The University Of Minnesota Inhibition of undesired effects of platinum(II) compounds
US4762705A (en) 1981-11-10 1988-08-09 Adolf W. Schwimmer Cancer therapy with interferon
US4645661A (en) 1984-06-29 1987-02-24 St. Jude Children's Research Hospital Method for alleviating cisplatin-induced nephrotoxicity and dithiocarbamate compounds for effecting same
US5187193A (en) 1988-09-12 1993-02-16 University Of Rochester Method for stimulating transplanted bone marrow cells
US5035878A (en) 1988-09-12 1991-07-30 University Of Rochester Use of dithiocarbamates to counteract myelosuppression
JPH04202139A (ja) 1990-11-30 1992-07-22 Tosoh Corp 血管新生抑制剤
JP3426599B2 (ja) 1991-11-08 2003-07-14 ヘモゾル インコーポレイテッド 薬物担体としてのヘモグロビン
US5380747A (en) 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5821260A (en) 1992-10-30 1998-10-13 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5792787A (en) 1995-06-07 1998-08-11 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
JP2002503214A (ja) 1996-11-06 2002-01-29 ディー． フェイマン，モーリス グルタミン酸関連疾患の処置のための方法
IL122891A0 (en) 1998-01-11 1998-08-16 Yeda Res & Dev Pharmaceutical compositions comprising a thiocarbamate
IL122892A0 (en) 1998-01-11 1998-08-16 Yeda Res & Dev Pharmaceutical compositions comprising a thiocarbamate

Also Published As

Publication number Publication date
EP1214063B1 (de) 2005-07-27
EP1214063A1 (de) 2002-06-19
CA2384059A1 (en) 2001-03-15
DE69926407D1 (de) 2005-09-01
US20030065026A1 (en) 2003-04-03
CA2384059C (en) 2010-06-22
US6589987B2 (en) 2003-07-08
AU2025500A (en) 2001-04-10
DE69926407T2 (de) 2006-05-24
JP2003514769A (ja) 2003-04-22
AU782029B2 (en) 2005-06-30
ES2244237T3 (es) 2005-12-01
WO2001017522A1 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
ATE300291T1 (de) Behandlung von krebs mit tetraethylthiuramdisulfid
DE60136730D1 (de) Methode zur behandlung von krebs mit dithiocarbamat-derivaten
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
MY140767A (en) Compounds, methods and compositions
ATE355079T1 (de) Behandlung von prostata-krebs mit anti-erbb2 antikörpern
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
TW200510927A (en) Stimulus-sensitive composition, compound and pattern formation method using the stimulation-sensitive composition
GEP20084539B (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
DE69902154D1 (de) Eisen-dextran verbindung zur verwendung als komponente in einer therapeutischen zusammensetzung zur behandlung oder prophylaxe von eisenmangel, sowie verfahren zur herstellung der eisen-dextran verbindung und ihre anwendung zur herstellung einer parenteral anwendbaren therapeutischen zubereitung.
ATE474946T1 (de) Elektrode für die behandlung von oberflächen mit elektrischen entladungen, verfahren zur behandlung von oberflächen mit elektrischen entladungen und vorrichtung zur behandlung von oberflächen mit elektrischen entladungen
ZA200500908B (en) Ruthenium anticancer complexes
AU2003273176A1 (en) Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
ATE415161T1 (de) Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
AU3052799A (en) Pharmaceutical compositions comprising erythropoietin for treatment of cancer
DE60120162D1 (en) Polyamin-analoge als cytotoxische wirkstoffe
ATE272404T1 (de) Verwendung von taurolidine zur herstellung eines arzneimittels zur behandlung von leukämien
WO2003073857A3 (de) Biologisch aktive kupferorganische mittel
ATE243522T1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
NO20001758L (no) FremgangsmÕter og blandinger for behandling av leddgikt
WO2000004153A3 (en) Repression of cell transformation with human pea3
MXPA03006742A (es) Uso de buprenorfina para la terapia de la incontinencia urinaria.
ATE358495T1 (de) Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea
ATE365718T1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
BG103087A (en) Method for the preparation of naphthiridons and intermediate compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties